

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

VOLUNTARY ANNOUNCEMENT EXPANSION OF GAURUNNING® (VELAGLUCERASE-BETA FOR INJECTION) INTO NORTH AFRICAN MARKET

This announcement is made by CANbridge Pharmaceuticals Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to update the shareholders and potential investors of the Company on the latest business development of the Group in relation to the expansion of Gaurunning® (velaglucerase-beta for injection) (“**Gaurunning**”) into the North African market.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Group has fully initiated the registration procedures and commercial readiness work for Gaurunning to cover a key North African market, and launch preparations in the region have commenced. The Group’s entry into the North African market, a region with sizable market potential and unmet clinical needs, marks the first step for Gaurunning to expand into a growing global Gaucher disease market.

Gaurunning has been granted marketing approval by the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (the “**PRC**”) on May 15, 2025 and is the first domestically independently developed long-term enzyme replacement therapy approved in the PRC for adolescents aged 12 and above and adults with Type I and Type III Gaucher disease. Gaurunning is the Company’s first in-house developed enzyme replacement therapy, and the Company holds global proprietary rights to develop and commercialize Gaurunning. As an innovative biologic drug, Gaurunning is positioned as an alternative to comparable imported products. The expected lower treatment costs will enhance treatment accessibility and sustainability for Gaucher disease patients globally. In addition, an NMPA-approved registration trial is ongoing, aiming to expand Gaurunning’s label to patients aged 2 to under 12.

The Company considers that the expansion of Gaurunning into the North African market represents an important milestone for the international rollout of Gaurunning into the global Gaucher disease market. Such expansion is expected to not only enhance treatment accessibility for Gaucher disease patients in North Africa, but also diversify the Group’s revenue mix, strengthen its profit base and deliver long-term value to shareholders over the medium to long term.

As at the date of this announcement, the Group is progressing with the registration procedures and commercial readiness work as mentioned above, and no formal sales revenue has yet been derived from the North African market in respect of Gaurunning. The completion of the applicable registration procedures with the relevant health authorities remains subject to, among other things, review and approval by such authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, July 30, 2026

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.